Original citation:
Permanent WRAP url:
http://wrap.warwick.ac.uk/52061

Copyright and reuse:
The Warwick Research Archive Portal (WRAP) makes the work of researchers of the University of Warwick available open access under the following conditions. Copyright © and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable the material made available in WRAP has been checked for eligibility before being made available.

Copies of full items can be used for personal research or study, educational, or not-for-profit purposes without prior permission or charge. Provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Publisher's statement:

A note on versions:
The version presented here may differ from the published version or, version of record, if you wish to cite this item you are advised to consult the publisher’s version. Please see the 'permanent WRAP url' above for details on accessing the published version and note that access may require a subscription.

For more information, please contact the WRAP Team at: wrap@warwick.ac.uk
Contested Psychiatric Ontology and Feminist Critique: ‘Female Sexual Dysfunction and the DSM

1. Introduction

‘Female Sexual Dysfunction’ (FSD) is a term that has gained in medical, psychiatric and media prominence in recent decades, especially in the last fifteen years. It is not in itself a diagnostic category, but has gained a currency that can sometimes suggest otherwise. Female sexual problems are currently classified in the American Psychiatric Association's fourth edition of the Diagnostic and Statistical Manual (DSM) (APA, 2000), in a section on Sexual Dysfunctions (separate from both the paraphilias and gender identity disorders), and assembling diagnoses relating to desire, arousal, orgasm, and pain (see Table 1). The DSM’s rise has been much criticized, and while the growing discussions of ‘FSD’ are praised by researchers and scientists as an index of a long overdue attention to women’s sexuality – a triumph of feminism (Basson et al 2001; Berman and Berman, 2001) - critics have underscored the link between this renewed medical attention and pharmaceutical interests in launching a compound comparable to Viagra for ‘Erectile Dysfunction’ (Tiefer 2008; Kaschak & Tiefer, 2001; Loe, 2004).

The FSD debate plays itself out in the public and popular domains as well as in the medical, psychiatric, and sexological realms. Existing historical scholarship on female sexuality in the postwar period focuses primarily on sexology (e.g. Gerhard, 2001; Irvine, 2005). In this article, I suggest that analysis of FSD benefits both from scrutiny of a wider range of sources (especially since the popular and scientific cross-pollinate), and from an approach from the history of psychiatry, in particular one
which probes debates about the ontology and etiology of sexual disorders, and the relationship between feminism and psychiatry in the postwar period. I suggest that existing literature on FSD has not yet posed some of the most important and salient questions at stake in writing about women’s sexual problems in this period, and can only do this when the relationship between ‘second-wave’ feminism, [postfeminism], psychiatry, and psychoanalysis becomes part of the terrain to be analysed, rather than the medium through which analysis is conducted.

I begin by outlining a brief sketch of female sexual problems in the twentieth century, and their rendering in the first two postwar DSMs. I then give an account of the emergence of DSM-III in 1980, and the classifications of sexual disorders in this manual. I then discuss the reification of ‘FSD’ as a term, in relation to Viagra’s emergence in the late 1990s, and then discuss the recent activism and scholarship around FSD. I explore the multiplicity of FSD that emerges when one examines a wider range of sources, but also underscore a reinscribing of anxieties about psychogenic etiologies. I then argue that what makes the FSD case additionally interesting, over and above other conditions with a contested status, is the historically complex relationship between psychiatry and feminism that is at work in contemporary debates. I conclude with some thoughts about ‘post-feminism’ and the historiographical challenges raised by FSD.

2. Sexual problems and the Diagnostic and Statistical Manual of Mental Disorders.

Women’s sexual problems have been written about prolifically during the twentieth century, in sexological, gynecological, psychiatric, and psychoanalytic literature, as
well as marital advice material (e.g. Ellis, 1897-1928; Krafft-Ebing, 1899; Hitschmann and Bergler, 1936; Stekel, 1936; Stopes, 1918; Wright, 1930; Van de Velde, 1928; Gray, 1923; see Lunbeck, 1994; Downing, 2004; Irvine, 1990; Maines, 1999; Cook, 2004; Cryle, 2009, Angel, 2010). Psychiatry has been salient in these discussions due to the mutually entangled development of psychiatry, sexology, and criminology in the last quarter of the nineteenth century (Foucault, 1979; Bland & Doan, 1998; Davidson, 2001). A forensic rationale fostered a focus, late nineteenth- and early twentieth-century sexology on sexual behaviours and identities, with the reification of classifications such as homosexuality, sadism, masochism, and fetishism. Frigidity – and its flip-side, nymphomania – were much-invoked preoccupations in the first half of the twentieth century, enduring until the 1960s at least; other concepts throughout the century have included sexual anaesthesia, sexual inhibition, anorgasmia or preorgasmia, and, from the 1970s, sexual dysfunction. Frigidity especially has been a semantically shifting term variously meaning women's natural lack of desire their unnatural failure to experience a normal desire, failure to become aroused, failure to reach orgasm, or failure to reach vaginal orgasm (L. Loewenfeld, 1899; Acton, 1862, quoted in Ellis, 1908: 157-8; Hitschmann & Bergler, 1936; Stekel, 1936; Huhner, 1937). A vast literature has documented the neo-Freudian linking of a range of social and psychological ills to a clitoral, rather than a vaginal, sexuality, where the outlining of norms for female sexuality has functioned as a way of defining norms of femininity and heterosexuality (e.g. in Abraham, 1920; Bonaparte, 1953; Deutsch, 1944; see Buhle, 1998; Lunbeck, 1994; Irvine, 1990; Maines, 1999; Downing, 2004).

In the postwar period, the American Psychiatric Association (APA) and its DSM loom increasingly large in psychiatry and in matters sexual. In its first edition in
1952 (an attempt to consolidate the many local variations to the American Medico-Psychological Association’s existing nomenclature and a proliferation of military nomenclatures), problems such as impotence and frigidity are an instance of 'Psychophysiological autonomic and visceral disorders' (under a larger group of 'Disorders of psychogenic origin or without clearly defined physical cause or structural change in the brain'), of which a 'psychophysiological genito-urinary reaction' is an instance. We are told that these include 'some types of menstrual disturbance, dysuria, and so forth, in which emotional factors play a causative role' (APA, 1952: 30). (See table 2).

These disorders represent the visceral expression of affect that is often 'prevented from being conscious'. Symptoms are due to a 'chronic and exaggerated state of the normal physiological expression of emotion, with the feeling, or subjective part, repressed. Such long continued visceral states may eventually lead to structural change' (ibid.: 29).

In the 1968 DSM-II (see Table 3), we see a slight variation of this; ‘psychophysiological disorders’ include ‘genito-urinary disorders such as disturbances in menstruation and micturition, dyspareunia, and impotence in which emotional factors play a causative role' (APA, 1968: 47). These ‘Psychophysiological disorders’ are characterised by

'physical symptoms that are caused by emotional factors and involve a single organ system, usually under autonomic nervous system innervation. The physiological changes involved are those that normally accompany certain emotional states, but in these disorders the changes are more intense and sustained. The individual may not be consciously aware of his emotional state' (ibid: 46).
Little detail is given, then, of the specific kinds of disorders included in these categories (in DSM-I, readers are told that each diagnosis of ‘Psychophysiologic autonomic and visceral disorders’ will be ‘amplified with the specific symptomatic manifestations, e.g. anorexia, loss of weight, dysmenorrhea, hypotensions, and so forth’; APA, 1952: 29), and the kinds of disorders enumerated are not meant to be comprehensive. An etiological process is posited, and it is the process – rather than its specific manifestations – that is salient. In their focus on unconscious, repressed emotions, the manuals’ terminology reflects the importance within American psychiatry, between the 1930s and 1960s, of an American-inflected psychoanalysis (Hale, 1995); in their emphasis on physiological changes which accompany certain emotions, and eventually, if sustained for long enough, lead to structural damage, they reflect the influence of a psychosomatic medicine much shaped by Franz Alexander (Alexander, 1932, 1950; Brown 2000, Greco 1998). Moreover, the manuals, in their emphasis on mental illness as on a continuum with health, the manuals also voice the influence of Adolf Meyer’s psychobiology, in which environmental factors interacted with certain predisposing factors in an individual to determine his or her capacity to adapt to that environment (Meyer, 1952). The DSM-III of 1980, however, ushers in significant changes in classification, marking an important shift in psychiatry’s twentieth-century history.

3. DSM-III

The DSM-III of 1980 emerged out of a period of intense controversy and questioning in the psychiatric profession and beyond. Psychoanalysis was at the core
of American psychiatry by the 1950s, but increasingly competing with other emerging forms of psychotherapy, and increasingly challenged by a critique of its scientific validity by academic psychologists, behaviourists, and philosophers questioning the very possibility of it generating verifiable predictions and testable theories (see Eysenck, 1959; Eysenck, 1965(a), 1965 (b)), Popper, 1963; Hook, 1959, Fisher & Greenberg, 1977; Freedheim, 1992; Luborsky,1975; Wallerstein, 1966; see Hale, 1995, Ch. 17). In addition, insurers were becoming unwilling to fund long psychoanalytic treatments whose efficacy was under question (Mayes & Horwitz, 2005). And the critique of psychoanalysis overlapped with some strands of the ‘anti-psychiatry’ movement, which challenged what it saw as diagnostic promiscuity and abusive and authoritarian relationships to the patient – with some critiques focusing particularly on the gender biases at work in psychoanalysis† (Szasz, 1962; Laing, 1960, 1964; Scheff, 1966; Goffman, 1961; Becker, 1963; Sulloway, 1979; Roazen, 1976; Brome, 1967; Medawar, 1975; Gelfman, 1969; Fliegel, 1973; Gilman, 1971, 1977; Friedan, 1963; Chesler, 1974; Millett 1970; see Grob, 1991; Hale, 1995; Shorter, 1997; Healy, 2002, 1997; Dain, 1989; Nye, 2003, Osborne, 1992; Appignanesi & Forrester, 2000; Tomes, 1994).

This scientific and cultural dissatisfaction was reflected in professional concern over diagnostic confusion and classificatory unreliability, with stark disparities in diagnostic trends causing embarrassment (see Stengel, 1959; Kramer, 1969; Kendell et al 1971; WHO, 1973). In the late 70s at the APA, Robert Spitzer, trained in both medicine and psychoanalysis, was appointed to the new Task Force to revise the DSM. He and his collaborators were committed to several axioms about psychiatry and mental illness that overturned the key assumptions of previous DSMs; namely, that there is a boundary between the normal and the sick; that there are
discrete mental illnesses; and that the focus ‘of psychiatric physicians should be particularly on the biological aspects of mental illness’ (Klerman, 1978: 104, see Bayer & Spitzer, 1985). The DSM-III sought to remove etiological assumptions (of a psychoanalytic kind, emphasizing neurosis and defenses) that it argued were unsupported. Disorders were discrete, and operationalised reliably by sets of symptom criteria (Rogler, 1997); an effect, argues Healy, of the rise of the randomised, placebo-controlled trial to test new medications required by the FDA to provably target clearly definable illness (see Healy, 1997, 2002; Pignarre, 2004). Highly controversial at the time for its excision of psychoanalytic conceptions, the DSM-III has consistently provoked controversy since, though latterly focused on the DSM’s expansion and its role in providing a rationale for pharmaceutical products. (Mayes & Horwitz 2005, Horwitz & Wakefield, 2007; Kirk & Kutchins, 1992; Kutchins & Kirk, 1997; Angell, 2011; Watters, 2010; Lane, 2007; Lakoff, 2005; Moynihan & Mintzes, 2010). For good or for ill, the DSM is now ‘connective tissue for biomedical psychiatry’, binding together measurement tools, diagnosis, treatment, research, drug assessment, epidemiology, insurance, and the law (Lakoff, 2005: 13).

4. The DSM-III and sexual dysfunctions

DSM-III yielded an increasingly detailed and differentiated classification of disorders, subsumed under a new splitting of diagnostic areas (e.g. Neurotic Disorders were dispensed with, but symptomatic remnants were distributed into the affective, anxiety, somatoform, and dissociative disorders) (see Rogler, 1997). The manual reorganises the two categories of sexual problems that existed in DSM-I and –II; instead of entirely separate categories and chapters for Sexual Deviations and
Psychophysiological Genito-urinary Disorders, in DSM-III we have an overarching chapter on 'Psychosexual Disorders'. (See Table 4.)

This is broken down into gender identity disorders, paraphilias, and psychosexual dysfunctions (with the latter using gender as a defining principle). The revised DSM-III-R of 1987 changed 'Psychosexual Dysfunctions' to 'Sexual Dysfunctions', and lists the various disorders under the overarching categories of Sexual Desire Disorders, Sexual Arousal Disorders, Orgasm Disorders, and Sexual Pain Disorders, amongst other changes (see Table 5). DSM-IV (1994) remains much the same, except that Inhibited Orgasm becomes Orgasmic Disorder. (See table 1).ii

The classification, since DSM-III, is much indebted to the work of Masters and Johnson, whose *Human Sexual Response* and *Human Sexual Inadequacy* were published in 1966 and 1970 respectively. Masters and Johnson were not the first to approach sexual problems with a form of behavioural conditioning, or to emphasise the clitoris in female sexual pleasure (Rachman, 1961; Lazarus, 1963; Kinsey et al, 1953; see also Downing, 2004). But their detailed physiological studies heralded the professionalisation of a behaviouristically-inflected sex therapy. Concerned to draw a near-total equivalence between male and female sexual functioniii, they outlined a four-stage Human Sexual Response Cycle (excitement, plateau, orgasm, and resolution), and three female sexual disorders: dyspareunia, vaginismus, and orgasmic dysfunction (primary and secondary) (Masters & Johnson 1966, 1970). (The problems for men were premature ejaculation, ejaculatory incompetence, and primary and secondary impotence).

Their ideas and nomenclature were mediated through Helen Singer Kaplan, who was a member of the Sexual Disorders Committee for DSM-III, and a sex therapist and psychoanalyst who sought to combine behaviourist and psychoanalytic
models in her work. She modified their nomenclature into a three-stage model of desire, excitement, and orgasm, incorporated into the document (APA, 1980; Tiefer, 2004, 51-52). Together with psychoanalyst Harold Lief, who also served on the DSM-III Sexual Disorders Committee, she ensured that problems of desire, as well as those of arousal and orgasm, were foregrounded (see Kaplan, 1977 and 1979; Lief, 1977). APA archival material, however, also reveals that psychoanalyst Robert Stoller, with whom Spitzer kept up a detailed correspondence, similarly (and earlier) suggested abandoning Masters and Johnson’s distinction between the excitement and plateau phases:

There is one issue with which I am out of step as compared to other colleagues in sex research. I am not sure there is good reason to separate out an excitement phase from a plateau phase. I do not believe that what is called ‘plateau’ is anything other than excitement. It is as if we were to divide excitement into a number of nondistinguishable episodes; such distinctions have no real function. (Stoller, 1977).

This renewed emphasis on desire – problems of which had been a significant component of the neo-Freudian writings on frigidity – undid an emphasis on the mechanics of arousal and orgasm in Masters and Johnson. Kaplan’s categories of ‘inhibited’ desire, excitement, orgasm reinscribed a psychoanalytic affinity, with the concept of inhibition containing within it the psychoanalytic connotations of symptoms resulting from the defenses mounted against anxiety. So while criticisms of the DSM’s FSD nomenclature have tended to focus on their allegedly uncritical adoption of a flawed and mechanistic Masters and Johnson model (Tiefer, 2004), and criticisms of the methods and rationale of the DSM-III ‘revolution’ have underlined
Spitzer’s ruthless eviction of psychoanalysis from the manual (and the profession) (Kutchins & Kirk, 1997), it appears that, at least for the Sexual Disorders, this narrative of eviction does not hold up so well, suggesting that a vision of the move to DSM-III as involving a stark and wholesale shift away from psychoanalytic concepts is in need of some refinement.

5. ‘Female Sexual Dysfunction’ and ‘Erectile Dysfunction’

In Masters and Johnson’s books, the term ‘female sexual dysfunction’ operated simply as a generic description rather than as a specific diagnosis; it signified any problem with sexual function as identified in the human sexual response cycle. But the term ‘Female Sexual Dysfunction’ becomes more prominent after their publications, however. It begins to appear in medical and scientific journals as a phrase only from 1977 onwards; half a dozen results appear in the 70s, and the same number in the 80s – a period when the term frigidity is waning in frequency. Occurrences of ‘FSD’ from the 90s onwards jump to being in the 500s. And yet there is in fact no such term ‘FSD’ in the DSMs; the chapter headings are ‘Psychosexual Disorders’ (DSM-III) or ‘Sexual Disorders’ (DSM-IIIR), under which the various subtypes (Female Sexual Arousal Disorder, Orgasmic Dysfunction, etc) appear.

This jump in FSD discourse occurs around the time of Viagra’s licensing for Erectile Dysfunction (ED) in 1998. Viagra’s apparently phenomenal success, and its astounding sales, put a premium on finding a similar drug for women. Pharmaceutical companies rushed to test Viagra in women, and seek to develop other compounds (Loe, 2004; Hartley, 2003, 2006). What we see, from the 1990s onwards, is a significant slippage between ‘FSD’ as a generic umbrella term - where the general
type of dysfunctions are sexual, and the ‘female’ works as a qualifier – to ‘FSD’ figuring as a condition in itself, a slippage enabled by the use of the singular term ‘dysfunction’. An example is a 1999 article by Jennifer and Laura Berman and Irwin Goldstein (prominent and prolific authors – the former in scientific and popular texts - on ED and FSD), which opens thus: ‘Female sexual dysfunction is age-related, progressive, and highly prevalent, affecting 30% to 50% of women’ (Berman et al, 1999, p. 385).

While they go on to specify particular areas of diagnosis such as ‘vaginal lubrication, pain and discomfort with intercourse, decreased arousal, and difficulty achieving orgasm’, they also state that ‘our knowledge and understanding of the anatomy and physiology of the female sexual response and the pathophysiology of female sexual dysfunction is limited.’ And yet, having roll-called some of the diversity of sexual problems, the slippage to the phrase ‘pathophysiology of female sexual dysfunction’ implies assumes, that the pathways to these diverse phenomena is one and the same, though it remains to be clearly elucidated. In other words, it casts ‘female sexual dysfunction’ as a condition in itself. This pattern is much repeated elsewhere, and articles frequently use the term ‘FSD’ in the title, but quickly move in the text to specifying disorders under consideration (O’Donohue et al, 1997; Sarwer & Durlak, 1996). A recent example is Figueroa-Haas (2012), who uses ‘FSD’ in the title, and writes the following:

Female sexual dysfunction (FSD) occurs when a woman is unable to fully experience pleasure during sexual activity. This dysfunction can affect a woman’s quality of life and lead to personal distress and interpersonal impairments. It is
defined as disorders of sexual desire, arousal, orgasm, and sexual pain. An estimated 40% of women are affected by sexual dysfunction and 1 in 4 is unable to achieve orgasm (p. 156).

In this particularly confused example, FSD is cast as a disorder in itself, offering a definition of ‘FSD’ as ‘disorders of desire, arousal’ and so on – whereas these categories are not definitions of a disorder, but the diagnostic categories subsumed under a generic term for them. Moreover, it emphasizes pleasure, which potentially brackets out desire problems.

What we are seeing here is FSD being used as an analogue – a counterpart – to ED, as in an article entitled ‘Lifestyle/Dietary Recommendations for Erectile Dysfunction and Female Sexual Dysfunction’ (Esposito & Giugliano, 2011). But ED is one diagnostic category applicable to men in the Sexual Disorders section of the DSM, while FSD is not its equivalent – it is a generic umbrella term for diagnoses that vary significantly. This reification of ‘FSD’ both reflects and bolsters the desire to see ‘FSD’ as a discrete, bounded diagnostic category amenable to a technology that would target it in the allegedly specific way Viagra did for ED – a desire that nonetheless has yielded little in the way of concrete results.

6. Activism and Scholarship

The rise of ‘FSD’ and pharmaceutical efforts around it has provoked considerable controversy as well as activism. New York sexologist Leonore Tiefer founded the New View Campaign, ‘challenging the medicalisation of sex’ (see Kaschak & Tiefer, 2001), after the increase, post-Viagra, in the ‘marketing’ of FSD, having previously
written about ED (Tiefer, 1994, 1995). The campaign sees Viagra as reinforcing a mechanical view of sexuality, rendering penetration and orgasm the pinnacle of sexual activity, and expressing heteronormative ideals of sexual behaviour. It argues that FSD discourse reduces sexuality to the purely biological as malfunctions of vascular, hormonal or cerebral systems to be fixed by pharmacological intervention, suggesting instead that female sexual problems especially are highly contextual - the result of social, cultural, and political factors (lack of communication between partners; exhaustion due to inequalities in child-rearing and housework; anxieties about body image; violence from sexual partners; and misunderstandings of female anatomy; (see http://www.newviewcampaign.org/manifesto.asp). The campaign has received growing press coverage in the last few years (Vernon, 2010, Sample, 2009, Independent, 13 June 2010; Laurence, 2010, Independent, 22 June 2010).

The campaign is also interlinked with a growing scholarship on FSD, the DSM, and pharmaceutical developments for sexual problems (much coming from social science, qualitative research, and science studies), part of a larger movement challenging the ‘medicalisation’ of problems seen as social, political, contextual and relational in nature (Cacchioni, 2007; see Potts 2000, Potts et al 2004, Potts et al 2003 for material on masculinity and Viagra; Ramage, 2006a; Ramage, 2006b; Fishman, 2004, Nicolson & Burr, 2003 Kaschak and Tiefer; Potts, 2008). Polemical and general audience works are also interlinked with the campaign (Drew, 2003, Moynihan & Cassels, 2005, Moynihan & Mintznes).

Many of these works owe much in spirit to the discourses of ‘anti-medicalisation’ that have been such a prominent part of debates about medicine and psychiatry since the 1960s. And they owe much to a component of second-wave feminism, suspicious of psychiatric expertise and professional expansion of authority
over women’s health, bodies, and minds (e.g. ‘Towards a Feminist Sex Therapy’, in Tiefer, 2004).

That the existing scholarship takes its impetus largely from activist concerns has some important methodological consequences. It necessitates and explains a focus on the DSM and on pharmaceutical developments. But in consequence, it narrowly construes the FSD landscape, glossing over resources such as women’s magazines and self-help books, for instance, which speak in an emotional, psychological and behavioural register. Moreover, it also glosses over the multiplicity at work in medical texts themselves.

7. Multiplicity

Take, for example, the pages of *Cosmo*. Sex psychotherapist Rachel Morris responds to a letter about libido problems: ‘A lack of desire can be due to many things’, hormone imbalance included, ‘but usually it’s down to a psychological or emotional block. There are so many reasons to freak out about sex – what if I’m no good? What if I don’t orgasm? It could be that you let negative thoughts freeze desire before it starts….Adding pressure will only make it worse, and stress, depression and anxiety are libido killers. Sexuality can’t be forced – it has a life of its own. Talk to your GP and ask for psychosexual counselling.’

Similarly, Jennifer and Laura Berman, authors of the best-selling *For Women Only: A Revolutionary Guide to Overcoming Sexual Dysfunction and Reclaiming Your Sex Life*, and of *The Passion Prescription: Ten Weeks to Your Best Sex – Ever!*, and prolific in medical journals also, advocate a significantly medical and pharmacological framework for sexual problems, especially the virtues of Viagra and
testosterone; but they too see fantasy, imagination, and thoughts as key to ‘helping
yourself’ with your sexual problems. In these texts, emotional, behavioural, and
cognitive habits are on a par with medical drugs, pornography, and sex toys; factors
key to enhancing pleasure and overcoming sexual problems. Likewise, health
information websites such as Netdoctor identify a range of factors in sexual problems
(Webber & Delvin (a), and a representative article in the American Family Physician
lists, as possible causes of sexual problems: medicines; diabetes; high blood pressure;
alcohol; vaginal infections; menopause; depression, ‘an unhappy relationship or abuse
(now or in the past)’; the stresses of everyday life, or being ‘bored by a long-standing

The ontology of sexual problems we see in a range of resources is, I think,
more cacophonous and multiple than a focus on pharmacological reductionism
suggests. It is perhaps an index of a late twentieth- and early twenty-first century
‘surveillance’ medicine in which multiple symptoms and signs become risk factors for
future outcomes (Armstrong, 1995; Rose, 2007). And yet, while a great many things –
hormones and emotional blocks, as Cosmo tells us - are relevant to sexual problems,
they are not all equal.

A kind of ontological hierarchy is asserted in a range of texts, with those
construed as psychosomatic, psychological, or psychodynamic – as partaking of the
‘unscientific’ psychiatry which DSM-III overturned - figuring as morally and
scientifically fraught. A 2001 Consensus Report written by prominent urologists and
psychiatrists, for example, proposes a nomenclature that would cover both
‘psychogenic and organically based disorders’ (unlike the DSM, which it describes as
narrowly psychiatric, ‘not intended to be used for classification of organic causes of
female sexual dysfunctions’) (Basson et al, 2001: 92). This is a curious reading of the
DSM, given the latter’s insistence on its own nature as providing a medical nomenclature, and as etiologically neutral (APA, 1994: xvii-xviii). But it reveals thereby the ambivalence with which the past of psychiatry – with its etiologies that so prioritized psychogenic factors in causing symptoms – is experienced. Location in the DSM is problematic, signalling a discomfort with psychiatric theorising that also sustains the claim that female sexuality, unlike male sexuality, has not, historically, been the subject of medical scrutiny (Basson et al, 2001: 83-84) – a claim that overlooks the location of female sexual problems within sexological, psychiatric, and psychoanalytic work in the 20th century. As such, it reflects a contemporary discomfort with the psychodynamic past of psychiatry that necessitates defining it, retrospectively, as non-medical. Psychiatry, its own medical protestations notwithstanding, is experienced as a troubling fringe discipline with a troubling past: female sexual problems should be removed ‘from the realm of primarily psychiatric disorders… into the mainstream of research and treatment’ (Rosenthal, 2001: 203, emphasis mine).

The fraught status of the psychogenic etiologies associated with a psychiatry that has been left behind is also evident in responses to a British Medical Journal article in 2003 written by Ray Moynihan that described the ‘making of’ FSD by researchers with close ties to drug companies (Moynihan, 2003: 45). Outraged responses ensued. A nurse therapist wrote that FSD is not a ‘new, pharmaceutically manufactured condition’, and that it is ‘ignorant in the extreme’ to think that she is ‘only treating “social disorders”’ (Astbury-Ward, 2003). Sexual dysfunction is not, a patient wrote, a ‘fabrication’ of women’s imagination or of ‘corporate America’s financial imagination’ (Dionne, 2003). Another patient wrote that a woman is ‘effectively silenced by the constant response that it is psychological (i.e. that she is
imagining it’ (Lewis, 2003). Similarly, Jennifer and Laura Berman – a urologist and psychiatrist team write that they are ‘shocked’ to hear of doctors telling patients that their sexual problems are ‘emotional, relational, or due to fatigue from child rearing or their busy jobs’:

‘We hope that this book will serve as an antidote to what women have heard for decades. The problem is not just in your head. You are not crazy…..We are beginning to recognise female sexual dysfunction as a medical problem’ (Berman & Berman, 2001: x-xi).

In the wake of Viagra, much-cited articles state that the context of female sexuality is highly important, but their priority remains to frame FSD as medical rather than psychiatric or psychological, as in Berman et al (1999), which states that not all female sexual complaints are psychological, and that there are possible therapeutic options’ (p.389). This article, and others, frame the psychological as secondary matter, which rhetorically functions as a concession in the article; they also echo an aspect of the Viagra/ED debate, in which Viagra’s apparent success was invoked (though this is not logically compelling) as proof that ED is ‘physical’, not psychological (Berman et al, 2000; Park, Goldstein et al, 1997; Korenman, 1998; Goldenberg, 1998; Berman et al, 1999a; Berman et al, 1999b; Berman et al, 1999c; Berman et al, 2000; see Loe, 2004, Hartley, 2003).

We are seeing here the slippery power of terms with deep ontological and moral reverberations. Claims about what influences diagnostic categories, etiological narratives, and symptoms themselves are repeatedly interpreted as claims about the reality of symptoms. Describing a condition as psychological is interpreted as
meaning that it is non-physical; what is not physical is thought to be not real. So saying that something is psychological is equated with saying it is unreal, imaginary, or fake. ‘Psychosomatic illness’, in popular usage, tends to connote deception, if not of others then at least of oneself, raising sensitive questions about wilful motivation and individual culpability (Lawrie, 2000; Stone et al, 2004).

8. Psychiatry and feminism

The fraught ontologies in the FSD landscape are, to be sure, not dissimilar from controversies regarding other conditions, Chronic Fatigue Syndrome most notably, where bitter and tail-chasing debates ensue about the ‘reality’ of conditions (Prins et al, 2006). The ontological discomforts I outline here, however, are overlain with something else - the historically uncomfortable relationship between feminism, psychiatry, and psychoanalysis, which adds a complex dimension to this landscape.

The fact that FSD scholarship tends to be activist-related explains another phenomenon in the existing literature: a failure to scrutinize, as an object in landscape, the feminism which sustains the critique of it. Feminist critics were vocal in the criticisms of psychiatry, and especially of psychoanalysis, from the 1960s, underscoring gender biases and the violences these were seen to enable (e.g. Friedan, 1963; Chesler, 1964; Millett, 1970; also, in the 1980s, Masson, 1959, 1989). The figure of Freud looms large in these works; Millet described him as ‘beyond question the strongest individual counterrevolutionary force in the ideology of sexual politics’; and Anne Koedt framed the ‘myth of vaginal orgasms’ (1970) as his most pernicious legacy (a legacy repeatedly invoked elsewhere, see Maines, 1999, and a criticism by Lunbeck, 2002). Existing scholarship on female sexuality, psychiatry, medicine and sexology is emphatic in its recognition of the feminist stakes in understandings of
female sexual problems (Cook, 2004; Irvine, 1990; Gerhard, 2001). For Irvine, for example, the measure of sexology, and its history, is the extent to which it is compatible with ‘feminism’ (even if the nature of that feminism is not explicitly articulated or spelt out in the book). Indeed, the fields of women’s history, feminist critique, and the history of medicine themselves have a thoroughly intertwined, and immensely fruitful, history (Tomes, 1994).

While feminist critiques of FSD emphasise the social, psychological, and contextual factors involved in sexual problems, they sidestep the thorny question of psychodynamic understandings of symptoms, or of any potential role of the unconscious in forming symptoms. They articulate a complex position via the nature and causes of sexual problems, but do so under the shadow of the sins of the fathers – the abuses perpetrated in the name of psychiatric and especially psychoanalytic conceptions of sexuality. As such, it reveals its own historically contingent identity as part of a particular strand of Anglo-American second-wave feminism, evincing an antipathy towards the psychological discourses of sexuality associated with Freud – rather than as part of feminisms which have wrought sympathetic if critical engagement with psychoanalysis (Mitchell, 1974; Chodorow, 1989, Cixous, 1975, 1976; Irigaray, 1977). And while feminist critique of psychoanalysis emerged with good reason, it cannot simply be assumed, theoretically and methodologically, by scholarship that attempts to illuminate the postwar trajectory of female sexual problems within psychiatry and culture - given that the rejection of psychoanalysis by both feminist and psychiatric discourses is such a pivotal phenomenon in that landscape.

In seeking to understand the FSD landscape, I suggest, it is helpful to widen the lens of criticism from discerning the norms of sexuality and gender expressed in
explicitly medico-pharmaceutical discourse – vital though that is - to also scrutinising feminism itself as a category that is discursively managed across a range of realms: medical texts, popular texts, and indeed feminist texts themselves.

Debates about female sexual problems in the postwar period are characterised by ambivalences towards the past, and indeed towards the very act of looking back at the past. Medical, feminist and popular texts evince discomfort with harking back to the past of psychiatric theorising - which, in psychodynamic psychiatry, involved precisely a commitment to the importance of the past in creating symptoms. Moreover, scholarship on these matters embodies a reluctance to look back, inclusively, at the history of feminism itself: at its complex relationship to psychiatry and its past, and how that shapes the modes in which critique is articulated.

Angela McRobbie has described a post-feminist sexual contract, in which, under the guise of an equality assumed to have been achieved, young women are attributed with political, economic, and sexual capacity. ‘Young women are able to come forward’ – as high-achieving, economically powerful figures - ‘on condition that feminism fades away’, and that they abandon the critique of hegemonic masculinity and sexism associated with feminism (McRobbie, 2007: 720, 729). She implies that rejecting and historicizing feminism are essentially interwoven (McRobbie, 2009, p. 16). We are required to look back at feminism as something unnecessary, old, and worn, and the dismantling of feminist politics is, she argues, inextricably linked to the contemporary dismantling of feminism within the academy (ibid., p. 13).

What relationship, then, does this historical activity - of including feminism as a component in the landscape to be analysed - bear to a ‘post-feminist’ stance that has been diagnosed as a symptom of a contemporary rejection of feminism? How should
one look back, historically and critically, at the feminisms of the postwar period? It is my view that an adequate analysis of the landscape requires, in addition to a critical relationship to rejections of feminism, a critical relationship to modes of rejecting the activity of looking back at the past. FSD scholarship provides us, I think, with an opportunity – as yet not taken up – to rethink the relationships between ‘second-wave’ feminism, ‘post-feminism’, psychoanalysis, medicine and psychiatry. It provides an opportunity to think not only about the intertwined legacies of psychiatry and feminism, but also to listen to complex discourses about history itself; about what is past, and what is present. It is, in other words, an opportunity to ask, and to find out, what kind of scholarship this particular moment – in psychiatry, feminism, and their historiography - is challenging us to write.

Notes

i The catch-all term ‘antipsychiatry’ needs to be used with caution; as Colin Jones has underlined, it encompasses a very varied phenomenon made up of sometimes conflicting positions, amongst which a content-based critique of psychiatry; a ‘gestural politics of carnivalesque inversion and symbolic performance’, and the exploration of new paradigms of knowledge about what it is to be human; see Colin Jones, ‘Raising the Anti: Jan Foudraine, Ronald Laing and Anti-Psychiatry’, in Cultures of Psychiatry and Mental Health Care in Postwar Britain and the Netherlands (ed. Gijswijt-Hofstra M, Porter R), Rodopi, 1998.

ii DSM-V is, at the time of writing, being prepared, due to be published in 2013; it appears to be significantly reordering the sexual classifications, in particular collapsing desire and arousal problems into a category of Sexual Interest/Arousal Disorder in women, and combining Dsypareunia and Vaginismus into Genito-Pelvic Pain/Penetration Disorder (http://www.dsm5.org/Pages/Default.aspx, accessed 21 July 2011).

iii A commitment to equivalence has persisted into later DSMs, and has been the target of critique (Tiefer, 1995). It is also being rethought in current revisions for DSM-V, through the work of Rosemary Basson, and Lori Brotto, who both suggest female sexual response is more responsive and receptive, and less spontaneous, than male desire (Basson, 2002; Brotto, 2010).

iv Initial attempts to develop vasocongestive targeting arousal problems proved disappointing; efforts have since focused on ‘central pathways’ and the ‘desire centres’ of the brain, with testosterone and serotonin receptor antagonists candidates (e.g. flibanserin). The latter garnered much media attention, but was rejected by the FDA, which has not yet approved a pharmacological agent for FSD, though the European Medicines Agency has licensed Intrinsa, a testosterone patch for postmenopausal women with Hypoactive Sexual Desire Disorder (HSDD).
Bibliography


Huhner M. (1937) The Diagnosis and Treatment of Sexual Disorders in the Male and Female, Including Sterility and Impotence. Philadelphia: FA Davis.


NHSDirect, ‘A Healthy Sex Life’. NHS Direct.co.uk. [http://www.nhs.uk/Livewell/Goodsex/Pages/Talkaboutsex.aspx#old](http://www.nhs.uk/Livewell/Goodsex/Pages/Talkaboutsex.aspx#old)


http://www.netdoctor.co.uk/sex_relationships/facts/orgasmtrouble.htm#


Webber, C. & Delvin, D. (c) ‘Anxiety and Sex’, Netdoctor.co.uk.


vi The critique features prominently in Moynihan and Mintzes’s recent popular book, making use of the tremendously fruitful language of ‘construction’, but in ways that slip between questioning the validity of the FSD category, and indeed of the very task of classification - an *epistemological* point - and questioning whether someone has symptoms which the diagnosis claims to describe - questioning whether there is anything there to (mis)describe - an *ontological* point. This obfuscation in the use of the term is where interested parties — pharmaceutical companies, practitioners invested in the dissemination of FSD and treatments for it have immense leeway to accuse FSD critics of disregard for women. See Angel, 2012.

vii Downing, 2004, stands out somewhat in that it uses critical and queer theory to approach FSD.